Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies
Amount Raised
$120 Million
Round Type
Series B
San DiegoBiotechnologyHealth CareTherapeuticsDescription
Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, today announced the closing of a $120 million Series B financing. New investor Venrock Healthcare Capital Partners led the financing. Other new investors participating in the financing included Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Janus Henderson Investors, Logos Capital, RTW Investments, LP, Surveyor Capital (a Citadel Company), Wellington Management Company, and an undisclosed leading global investment firm. Existing investors, 5AM Ventures, RA Capital Management, and venBio Partners, along with strategic partners GC LabCell (Green Cross LabCell Corporation, KRX: 14451) and GC (Green Cross Holdings Corporation, KRX: 005250), also participated in the financing
Quick answer
Artiva Biotherapeutics raised $120 Million in a Series B round, dated February 26, 2021. Artiva Biotherapeutics is based in San Diego, California, United States.
- How much did Artiva Biotherapeutics raise?
- Artiva Biotherapeutics raised $120 Million in a Series B round on February 26, 2021.
- What does Artiva Biotherapeutics do?
- Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers.
- Where is Artiva Biotherapeutics based and how big is it?
- Artiva Biotherapeutics is based in San Diego, California, United States. Fundz records about 95 employees.
- Who are the decision-makers at Artiva Biotherapeutics?
- Fundz holds 1 contact at Artiva Biotherapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Artiva Biotherapeutics that raised within 45 days of this round, from Fundz verified event records.
- Aura Biosciences, Inc. raised $80M on April 6, 2021.
- AbSci Corp raised $125M on March 30, 2021.
- Chemomab Therapeutics Ltd raised $45M on March 30, 2021.
- Qihan Biotech raised $67M (Series A) on March 29, 2021.
- Azora Therapeutics, Inc. (DE) raised $291K on March 26, 2021.
- Scipher Medicine raised $82M on March 26, 2021.
Who to call at Artiva Biotherapeutics, and when
A new round usually means Artiva Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Artiva Biotherapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Artiva Biotherapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Artiva Biotherapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Artiva Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansArtiva Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.